CA2258090A1 - Chimeric mutational vectors having non-natural nucleotides - Google Patents
Chimeric mutational vectors having non-natural nucleotides Download PDFInfo
- Publication number
- CA2258090A1 CA2258090A1 CA002258090A CA2258090A CA2258090A1 CA 2258090 A1 CA2258090 A1 CA 2258090A1 CA 002258090 A CA002258090 A CA 002258090A CA 2258090 A CA2258090 A CA 2258090A CA 2258090 A1 CA2258090 A1 CA 2258090A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleobases
- strand
- type
- ribo
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 27
- 239000002773 nucleotide Substances 0.000 title claims description 33
- 239000013598 vector Substances 0.000 title abstract description 20
- 230000000869 mutational effect Effects 0.000 title abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 63
- 230000035772 mutation Effects 0.000 claims abstract description 39
- 101710163270 Nuclease Proteins 0.000 claims abstract description 15
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 14
- 239000002336 ribonucleotide Substances 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 107
- 238000000034 method Methods 0.000 claims description 47
- 150000001875 compounds Chemical class 0.000 claims description 32
- 239000012634 fragment Substances 0.000 claims description 32
- 239000003471 mutagenic agent Substances 0.000 claims description 27
- 230000004075 alteration Effects 0.000 claims description 18
- 230000000295 complement effect Effects 0.000 claims description 16
- 239000002777 nucleoside Substances 0.000 claims description 12
- 230000008859 change Effects 0.000 claims description 11
- 238000012217 deletion Methods 0.000 claims description 10
- 230000037430 deletion Effects 0.000 claims description 10
- 230000008439 repair process Effects 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 210000004940 nucleus Anatomy 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 10
- 108700001094 Plant Genes Proteins 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract description 52
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 21
- 230000006801 homologous recombination Effects 0.000 abstract description 13
- 238000002744 homologous recombination Methods 0.000 abstract description 13
- 108091028664 Ribonucleotide Proteins 0.000 abstract description 9
- 125000002652 ribonucleotide group Chemical group 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 5
- 208000026350 Inborn Genetic disease Diseases 0.000 abstract description 4
- 208000016361 genetic disease Diseases 0.000 abstract description 4
- 230000009261 transgenic effect Effects 0.000 abstract description 4
- 238000013461 design Methods 0.000 abstract description 3
- 239000005547 deoxyribonucleotide Substances 0.000 abstract description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 abstract description 2
- 238000001415 gene therapy Methods 0.000 abstract description 2
- 238000010276 construction Methods 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 74
- 108020004707 nucleic acids Proteins 0.000 description 27
- 102000039446 nucleic acids Human genes 0.000 description 27
- 150000007523 nucleic acids Chemical class 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 14
- 238000001890 transfection Methods 0.000 description 14
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 12
- 108091033380 Coding strand Proteins 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 238000012937 correction Methods 0.000 description 11
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 9
- 108700028369 Alleles Proteins 0.000 description 8
- 238000001712 DNA sequencing Methods 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- -1 i.e. Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108091093037 Peptide nucleic acid Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000001744 histochemical effect Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 125000003835 nucleoside group Chemical group 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000002798 spectrophotometry method Methods 0.000 description 5
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 4
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 102000001218 Rec A Recombinases Human genes 0.000 description 4
- 108010055016 Rec A Recombinases Proteins 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 150000008300 phosphoramidites Chemical class 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 208000007056 sickle cell anemia Diseases 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 101150040459 RAS gene Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003212 purines Chemical class 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 108700042226 ras Genes Proteins 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003146 transient transfection Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 101100243025 Arabidopsis thaliana PCO2 gene Proteins 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101710113436 GTPase KRas Proteins 0.000 description 2
- 208000015872 Gaucher disease Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- 244000301083 Ustilago maydis Species 0.000 description 2
- 235000015919 Ustilago maydis Nutrition 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 108060003196 globin Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- DSWNRHCOGVRDOE-UHFFFAOYSA-N n,n-dimethylmethanimidamide Chemical compound CN(C)C=N DSWNRHCOGVRDOE-UHFFFAOYSA-N 0.000 description 2
- 101800002712 p27 Proteins 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 150000008298 phosphoramidates Chemical class 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002342 ribonucleoside Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical compound NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100454435 Biomphalaria glabrata BG05 gene Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 101100327819 Caenorhabditis elegans chl-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102100033934 DNA repair protein RAD51 homolog 2 Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101100381516 Homo sapiens BCL2 gene Proteins 0.000 description 1
- 101001132307 Homo sapiens DNA repair protein RAD51 homolog 2 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 235000015250 liver sausages Nutrition 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- XTGGILXPEMRCFM-UHFFFAOYSA-N morpholin-4-yl carbamate Chemical compound NC(=O)ON1CCOCC1 XTGGILXPEMRCFM-UHFFFAOYSA-N 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- CPQCSJYYDADLCZ-UHFFFAOYSA-N n-methylhydroxylamine Chemical compound CNO CPQCSJYYDADLCZ-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000008223 ribosides Chemical class 0.000 description 1
- 125000000548 ribosyl group Chemical class C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/664,487 | 1996-06-17 | ||
| US08/664,487 US5731181A (en) | 1996-06-17 | 1996-06-17 | Chimeric mutational vectors having non-natural nucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2258090A1 true CA2258090A1 (en) | 1997-12-24 |
Family
ID=24666178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002258090A Abandoned CA2258090A1 (en) | 1996-06-17 | 1997-06-16 | Chimeric mutational vectors having non-natural nucleotides |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US5731181A (cg-RX-API-DMAC10.html) |
| EP (1) | EP0968224A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP4063326B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20000011075A (cg-RX-API-DMAC10.html) |
| AU (1) | AU732417B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2258090A1 (cg-RX-API-DMAC10.html) |
| NZ (1) | NZ333201A (cg-RX-API-DMAC10.html) |
| WO (1) | WO1997048714A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (163)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6524613B1 (en) | 1997-04-30 | 2003-02-25 | Regents Of The University Of Minnesota | Hepatocellular chimeraplasty |
| GB9711015D0 (en) * | 1997-05-28 | 1997-07-23 | Zeneca Ltd | Improvements in or relating to organic compounds |
| KR20010022652A (ko) * | 1997-08-05 | 2001-03-26 | 키메라젠, 인크. | 식물에서 국소적인 유전자변형을 유발하기 위한 혼성 이중나선올리고뉴클레오티드의 용도 |
| US6706693B1 (en) | 1997-08-13 | 2004-03-16 | The Uab Research Foundation | Vaccination by topical application of genetic vectors |
| US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
| US20030125278A1 (en) * | 1997-08-13 | 2003-07-03 | Tang De-Chu C. | Immunization of animals by topical applications of a salmonella-based vector |
| US20030045492A1 (en) * | 1997-08-13 | 2003-03-06 | Tang De-Chu C. | Vaccination by topical application of recombinant vectors |
| US6716823B1 (en) | 1997-08-13 | 2004-04-06 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom, and uses thereof |
| US7102055B1 (en) | 1997-11-18 | 2006-09-05 | Pioneer Hi-Bred International, Inc. | Compositions and methods for the targeted insertion of a nucleotide sequence of interest into the genome of a plant |
| AU1526199A (en) * | 1997-11-18 | 1999-06-07 | Pioneer Hi-Bred International, Inc. | Targeted manipulation of herbicide-resistance genes in plants |
| AU757672B2 (en) | 1997-11-18 | 2003-02-27 | Pioneer Hi-Bred International, Inc. | A method for directional stable transformation of eukaryotic cells |
| US6004804A (en) * | 1998-05-12 | 1999-12-21 | Kimeragen, Inc. | Non-chimeric mutational vectors |
| US6010907A (en) * | 1998-05-12 | 2000-01-04 | Kimeragen, Inc. | Eukaryotic use of non-chimeric mutational vectors |
| US6150105A (en) * | 1998-08-20 | 2000-11-21 | Genetic Assays, Inc. | Methods of screening nucleic acids for nucleotide variations |
| DE19956568A1 (de) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| AU2008202208C1 (en) * | 1999-01-30 | 2014-04-24 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a defined gene |
| EP2368575B1 (en) * | 1999-04-08 | 2014-10-01 | Intercell USA, Inc. | Dry formulation for transcutaneous immunization |
| US6348050B1 (en) * | 1999-04-30 | 2002-02-19 | Medtronic, Inc. | Infusion systems for creating microenvironments in a living body |
| US20040009936A1 (en) * | 1999-05-03 | 2004-01-15 | Tang De-Chu C. | Vaccine and drug delivery by topical application of vectors and vector extracts |
| JP2003502288A (ja) * | 1999-05-21 | 2003-01-21 | ザユニバーシティー オブ マイアミ | 固体組織中の内因性ヌクレオチド配列を変化させるためのキメラ突然変異ベクターの使用 |
| US6271360B1 (en) * | 1999-08-27 | 2001-08-07 | Valigen (Us), Inc. | Single-stranded oligodeoxynucleotide mutational vectors |
| EP1218524A2 (en) * | 1999-10-07 | 2002-07-03 | Valigen Inc. | Compositions and methods for plant genetic modification |
| AR025996A1 (es) | 1999-10-07 | 2002-12-26 | Valigen Us Inc | Plantas no transgenicas resistentes a los herbicidas. |
| WO2001049118A1 (en) * | 2000-01-03 | 2001-07-12 | Panagenic International, Inc. | Compositions comprising genome segments and methods of using the same |
| US6936467B2 (en) | 2000-03-27 | 2005-08-30 | University Of Delaware | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| AU4948801A (en) * | 2000-03-27 | 2001-10-08 | Univ Delaware | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| EP1284985A2 (en) * | 2000-05-17 | 2003-02-26 | University Of Delaware | Plant gene targeting using oligonucleotides |
| US6686188B2 (en) | 2000-05-26 | 2004-02-03 | Amersham Plc | Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle |
| US6656700B2 (en) | 2000-05-26 | 2003-12-02 | Amersham Plc | Isoforms of human pregnancy-associated protein-E |
| WO2001094610A2 (en) * | 2000-06-05 | 2001-12-13 | Thomas Jefferson University | Binary hybrid mutational vectors |
| NZ524366A (en) * | 2000-07-27 | 2005-12-23 | Univ Delaware | Methods for enhancing targeted gene alteration using oligonucleotides |
| US6875907B2 (en) | 2000-09-13 | 2005-04-05 | Pioneer Hi-Bred International, Inc. | Antimicrobial peptides and methods of use |
| US20020119570A1 (en) * | 2000-09-25 | 2002-08-29 | Kyonggeun Yoon | Targeted gene correction by single-stranded oligodeoxynucleotides |
| US20020123474A1 (en) * | 2000-10-04 | 2002-09-05 | Shannon Mark E. | Human GTP-Rho binding protein2 |
| US7560622B2 (en) | 2000-10-06 | 2009-07-14 | Pioneer Hi-Bred International, Inc. | Methods and compositions relating to the generation of partially transgenic organisms |
| US20040063922A1 (en) * | 2001-04-17 | 2004-04-01 | Conrad Charles A. | Methods and compositions for catalytic DNA exchange in a sequence specific manner |
| US7053195B1 (en) | 2001-06-12 | 2006-05-30 | Syngenta Participatious Ag | Locked nucleic acid containing heteropolymers and related methods |
| US20040078837A1 (en) * | 2001-08-02 | 2004-04-22 | Shannon Mark E. | Four human zinc-finger-containing proteins: MDZ3, MDZ4, MDZ7 and MDZ12 |
| WO2003013437A2 (en) * | 2001-08-07 | 2003-02-20 | University Of Delaware | Compositions and methods for the prevention and treatment of huntington's disease |
| WO2003013226A2 (en) * | 2001-08-09 | 2003-02-20 | Cibus Genetics | Non-transgenic herbicide resistant plants |
| US20030207327A1 (en) * | 2001-09-27 | 2003-11-06 | Kmiec Eric B. | Coisogenic eukaryotic cell collections |
| AU2002341905A2 (en) * | 2001-09-27 | 2003-04-07 | University Of Delaware | Composition and methods for enhancing oligonucleotide-directed nucleic acid sequence alteration |
| US20030105047A1 (en) * | 2001-11-30 | 2003-06-05 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by brain infusion of mutational vectors |
| US7566535B2 (en) * | 2002-03-07 | 2009-07-28 | University Of Delaware | Enhanced oligonucleotide-mediated nucleic acid sequence alteration |
| US20030228558A1 (en) * | 2002-06-11 | 2003-12-11 | Bloom William Dennis | Method of training brokers in a multi-level marketing business |
| WO2004026343A1 (ja) * | 2002-09-20 | 2004-04-01 | Sumitomo Phamaceuticals Co., Ltd. | 部位特異的遺伝子変換促進剤および遺伝子疾患治療剤 |
| AU2003282477A1 (en) * | 2002-10-07 | 2004-05-04 | Napro Bio Therapeutics, Inc. | Methods and compositions for reducing screening in oligonucleotide-directed nucleic acid sequence alteration |
| AU2003283217A1 (en) * | 2002-12-03 | 2004-06-23 | Aarhus Amt | Method for determing predisposition to manifestation of immune system related diseases |
| US20070072815A1 (en) * | 2004-05-04 | 2007-03-29 | Kmiec Eric B | Methods and kits to increase the efficiency of oligonucleotide-directed nucleic acid sequence alteration |
| WO2006071219A1 (en) | 2004-12-28 | 2006-07-06 | Pioneer Hi-Bred International, Inc. | Improved grain quality through altered expression of seed proteins |
| WO2006091194A1 (en) | 2005-02-23 | 2006-08-31 | North Carolina State University | Alteration of tobacco alkaloid content through modification of specific cytochrome p450 genes |
| US7524510B2 (en) * | 2005-02-23 | 2009-04-28 | The Uab Research Foundation | Alkyl-glycoside enhanced vaccination |
| US7680604B2 (en) | 2005-03-11 | 2010-03-16 | Roche Molecular Systems, Inc. | PCR elbow determination by rotational transform after zero slope alignment |
| WO2006119775A2 (en) | 2005-05-11 | 2006-11-16 | Aarhus Universitet | Method for diagnosis and treatment, of a mental disease |
| US20060272057A1 (en) | 2005-05-25 | 2006-11-30 | Pioneer Hi-Bred International, Inc. | Methods for improving crop plant architecture and yield |
| US7842856B2 (en) | 2005-08-25 | 2010-11-30 | The Board Of Trustees Of The University Of Illinois | Herbicide resistance gene, compositions and methods |
| US7671254B2 (en) * | 2005-08-25 | 2010-03-02 | The Board Of Trustees Of The University Of Illinois | Herbicide resistance gene, compositions and methods |
| CN101356279A (zh) | 2005-11-10 | 2009-01-28 | 先锋高级育种国际公司 | Dof(具有一指的dna结合)序列和使用方法 |
| US20070199096A1 (en) | 2005-11-14 | 2007-08-23 | E.I. Du Pont De Nemours And Company | Compositions and Methods for Altering Alpha- and Beta-Tocotrienol Content |
| WO2007073149A1 (en) * | 2005-12-22 | 2007-06-28 | Keygene N.V. | Alternative nucleotides for improved targeted nucleotide exchange |
| US7592505B2 (en) | 2005-12-30 | 2009-09-22 | Pioneer Hi-Bred International, Inc. | UDP-xylose synthases (UXS) polynucleotides, polypeptides, and uses thereof |
| CA3077776C (en) | 2006-01-12 | 2022-10-04 | Cibus Europe B.V. | Epsps mutants |
| RU2313349C2 (ru) | 2006-01-16 | 2007-12-27 | Михаил Аркадьевич Шурдов | Способ лечения онкологических заболеваний |
| CA2821436A1 (en) | 2006-02-09 | 2007-08-16 | Pioneer Hi-Bred International, Inc. | Genes for enhancing nitrogen utilization efficiency in crop plants |
| CA2649734A1 (en) | 2006-04-19 | 2007-11-01 | Pioneer Hi-Bred International, Inc. | Isolated polynucleotide molecules corresponding to mutant and wild-type alleles of the maize d9 gene and methods of use |
| AU2007363151B2 (en) * | 2006-06-28 | 2014-12-11 | Cibus Europe B.V. | Alkylester fatty acid blends and uses therefor |
| UA107442C2 (uk) | 2006-06-28 | 2015-01-12 | Nucelis Inc | Суміш жирних кислот та її застосування |
| EP3066934A1 (de) | 2006-10-06 | 2016-09-14 | BASF Plant Science GmbH | Verfahren zur herstellung mehrfach ungesättigter fettsäuren in transgenen organismen |
| RU2345792C2 (ru) * | 2007-04-03 | 2009-02-10 | Михаил Аркадьевич Шурдов | Способ лечения онкологических заболеваний |
| UA125846C2 (uk) | 2007-04-04 | 2022-06-22 | Басф Плант Саєнс Гмбх | Мутант ahas |
| EA036108B1 (ru) * | 2007-04-04 | 2020-09-29 | Басф Се | Резистентные к гербицидам растения brassica и способы применения |
| CN101679493A (zh) | 2007-05-25 | 2010-03-24 | 克罗普迪塞恩股份有限公司 | 在植物中通过调节玉米alfin的产量增强 |
| EA202092479A3 (ru) * | 2007-10-05 | 2021-06-30 | СИБАС ЕУРОП Би.Ви. | Растение и семя масличного рапса brassica napus, содержащие мутированные гены синтазы ацетогидроксикислот |
| US8124851B2 (en) | 2007-11-12 | 2012-02-28 | North Carolina State University | Alteration of tobacco alkaloid content through modification of specific cytochrome P450 genes |
| CN103952415A (zh) | 2007-11-20 | 2014-07-30 | 先锋国际良种公司 | 用于改善植物应激耐性的玉米乙烯信号转导基因及其调节 |
| EP2235187B1 (en) | 2007-12-21 | 2013-12-11 | Keygene N.V. | An improved mutagenesis method using polyethylene glycol mediated introduction of mutagenic nucleobases into plant protoplasts |
| WO2009143490A1 (en) | 2008-05-23 | 2009-11-26 | Cibus International, L.P. | Production of squalene using yeast |
| CN103834675A (zh) | 2008-09-26 | 2014-06-04 | 巴斯夫农化产品有限公司 | 除草剂-抗性的ahas-突变体及使用方法 |
| CN102197137A (zh) | 2008-10-30 | 2011-09-21 | 先锋国际良种公司 | 对谷氨酰胺合成酶(gs)进行操作以改善高等植物中的氮利用效率和籽粒产量 |
| CA2743707A1 (en) | 2008-12-04 | 2010-06-10 | Pioneer Hi-Bred International, Inc. | Methods and compositions for enhanced yield by targeted expression of knotted1 |
| PL2376638T3 (pl) | 2008-12-12 | 2014-01-31 | Basf Plant Science Gmbh | Desaturazy oraz sposób wytwarzania wielonienasyconych kwasów tłuszczowych w organizmach transgenicznych |
| EP2376637A1 (en) | 2008-12-22 | 2011-10-19 | Keygene N.V. | Use of double stranded rna to increase the efficiency of targeted gene alteration in plant protoplasts |
| AU2010204723A1 (en) | 2009-01-14 | 2011-08-18 | The Salk Institute For Biological Studies | Methods for screening and compounds that protect against amyloid diseases |
| US8716553B2 (en) | 2009-03-02 | 2014-05-06 | Pioneer Hi Bred International Inc | NAC transcriptional activators involved in abiotic stress tolerance |
| MX2011010845A (es) | 2009-04-14 | 2011-11-02 | Pioneer Hi Bred Int | La modulacion de acc sintasa mejora el rendimiento de las plantas en condiciones de bajo contenido de nitrogeno. |
| EP2427481A1 (en) | 2009-05-04 | 2012-03-14 | Pioneer Hi-Bred International Inc. | Yield enhancement in plants by modulation of ap2 transcription factor |
| CA2768571A1 (en) | 2009-07-24 | 2011-01-27 | Pioneer Hi-Bred International, Inc. | The use of dimerization domain component stacks to modulate plant architecture |
| RU2429019C2 (ru) * | 2009-08-03 | 2011-09-20 | Михаил Аркадьевич Шурдов | Способ лечения онкологических заболеваний |
| WO2011017492A2 (en) | 2009-08-05 | 2011-02-10 | Pioneer Hi-Bred International, Inc. | Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants |
| EP2483404A1 (en) | 2009-10-02 | 2012-08-08 | Pioneer Hi-Bred International Inc. | Down-regulation of acc synthase for improved plant performance |
| DK2504421T3 (en) * | 2009-11-23 | 2017-05-22 | Nucelis Inc | METHODS AND COMPOSITIONS FOR PREPARING SQUAL USING Yeast |
| US20110191903A1 (en) | 2009-12-31 | 2011-08-04 | Pioneer Hi-Bred International, Inc. | Engineering plant resistance to diseases caused by pathogens |
| CN102906267A (zh) | 2010-01-06 | 2013-01-30 | 先锋国际良种公司 | 玉米光合作用组织和非光合作用组织昼夜节律的鉴定及其在改良作物方面的用途 |
| BR112012018616A2 (pt) | 2010-01-26 | 2017-01-10 | Pioneer Hi Bred Int | marcador de polinucleotídeo, polinucleotídeo isolado, polipeptídeo transportador abc isolado, planta, célula, semente, método para seleção de uma planta ou germoplasma de soja, método de introgressão de um alelo de resistência a herbicida em uma planta de soja, método para conferir tolerância ou tolerância melhorada a um ou mais herbicidas, método para controlar de modo seletivo plantas daninhas em um campo contendo uma cultura |
| WO2011139431A1 (en) | 2010-05-06 | 2011-11-10 | Pioneer Hi-Bred International, Inc. | Maize acc synthase 3 gene and protein and uses thereof |
| US20120122223A1 (en) | 2010-08-03 | 2012-05-17 | Cibus Us Llc | Mutated protoporphyrinogen ix oxidase (ppx) genes |
| UA112969C2 (uk) | 2010-08-03 | 2016-11-25 | Сібас Юс Ллс | Рослина, стійка до одного або більше ррх-інгібуючих гербіцидів, яка містить мутантний ген протопорфіриноген ix оксидази (ррх) |
| CN103237894A (zh) | 2010-08-13 | 2013-08-07 | 先锋国际良种公司 | 包含具有羟基苯丙酮酸双加氧酶(hppd)活性的序列的组合物和方法 |
| WO2012028673A1 (en) | 2010-09-02 | 2012-03-08 | Ludwig-Maximilians-Universitaet Muenchen | Spontaneous organogenesis in plants |
| EP2426204A1 (en) | 2010-09-02 | 2012-03-07 | Ludwig-Maximilians-Universität München | Spontaneous nodule organogenesis in plants |
| EP2646549B1 (en) | 2010-12-02 | 2015-02-18 | Keygene N.V. | Targeted alteration of dna |
| US9518258B2 (en) | 2010-12-02 | 2016-12-13 | Keygene N.V. | Targeted alteration of DNA with oligonucleotides |
| BR112013027860A2 (pt) | 2011-04-29 | 2016-11-29 | Pioneer Hi Bred Int | ácido nucleico isolado, planta ou célula vegetal, método para aumentar a capacidade do dreno, acelerar a remobilização e/ou a senescência e a secagem de grão em uma planta, método para aumentar a tolerância a seca na ausência de uma penalidade de produtividade sob condições sem seca, cassete de expressão e método para reduzir a expressão de zmme293 ou a atividade de zmme293 em uma planta |
| WO2012174139A2 (en) | 2011-06-14 | 2012-12-20 | Synthon Biopharmaceuticals B.V. | Compositions and methods for making and b ioc ont aining auxotrophic transgenic plants |
| US20130097734A1 (en) | 2011-07-12 | 2013-04-18 | Two Blades Foundation | Late blight resistance genes |
| CN104093842B (zh) | 2011-10-31 | 2016-12-07 | 先锋国际良种公司 | 改善植物耐旱性、氮利用效率和产量 |
| CN104703998B (zh) | 2012-03-13 | 2020-08-21 | 先锋国际良种公司 | 植物中雄性育性的遗传减少 |
| WO2013138309A1 (en) | 2012-03-13 | 2013-09-19 | Pioneer Hi-Bred International, Inc. | Genetic reduction of male fertility in plants |
| US10045499B2 (en) | 2012-05-24 | 2018-08-14 | Iowa State University Research Foundation, Inc. | Arabidopsis nonhost resistance gene(s) and use thereof to engineer disease resistant plants |
| EP2885411B1 (en) | 2012-08-16 | 2018-12-05 | VIB vzw | Means and methods for altering the lignin pathway in plants |
| CN105008541A (zh) | 2012-12-21 | 2015-10-28 | 先锋国际良种公司 | 用于生长素类似物缀合的组合物和方法 |
| WO2014164014A1 (en) | 2013-03-11 | 2014-10-09 | Pioneer Hi-Bred International, Inc. | Genes for improving nutrient uptake and abiotic stress tolerance in plants |
| US9803214B2 (en) | 2013-03-12 | 2017-10-31 | Pioneer Hi-Bred International, Inc. | Breeding pair of wheat plants comprising an MS45 promoter inverted repeat that confers male sterility and a construct that restores fertility |
| WO2014164466A1 (en) | 2013-03-12 | 2014-10-09 | E. I. Du Pont De Nemours And Company | Methods for the identification of variant recognition sites for rare-cutting engineered double-strand-break-inducing agents and compositions and uses thereof |
| WO2014164074A1 (en) | 2013-03-13 | 2014-10-09 | Pioneer Hi-Bred International, Inc. | Enhanced nitrate uptake and nitrate translocation by over-expressing maize functional low-affinity nitrate transporters in transgenic maize |
| US20160017360A1 (en) | 2013-03-13 | 2016-01-21 | Pioneer Hi-Bred International, Inc. | Functional expression of bacterial major facilitator superfamily mfs gene in maize to improve agronomic traits and grain yield |
| CN105358696A (zh) | 2013-03-14 | 2016-02-24 | 希博斯美国有限公司 | 突变的丙二烯氧合酶2(aos2)基因 |
| CN105143248A (zh) | 2013-03-14 | 2015-12-09 | 先锋国际良种公司 | 玉蜀黍胁迫相关转录因子18及其用途 |
| HUE058351T2 (hu) | 2013-03-15 | 2022-07-28 | Cibus Us Llc | Célzott génmódosítás oligonukleotid-közvetített génjavítás alkalmazásával |
| WO2014152507A2 (en) | 2013-03-15 | 2014-09-25 | Pioneer Hi-Bred International, Inc. | Modulation of acc deaminase expression |
| US9957515B2 (en) | 2013-03-15 | 2018-05-01 | Cibus Us Llc | Methods and compositions for targeted gene modification |
| CA2903555A1 (en) | 2013-03-15 | 2014-09-18 | Pioneer Hi-Bred International, Inc. | Compositions and methods of use of acc oxidase polynucleotides and polypeptides |
| US12331303B2 (en) | 2013-03-15 | 2025-06-17 | Cibus Us Llc | Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair |
| ES2921207T3 (es) | 2013-03-15 | 2022-08-19 | Cibus Us Llc | Procedimientos y composiciones para aumentar la eficiencia de la modificación genética direccionada utilizando la reparación genética mediada por oligonucleótidos |
| US10017778B2 (en) | 2013-03-21 | 2018-07-10 | Vib Vzw | Means and methods for the reduction of photorespiration in crops |
| US11459579B2 (en) | 2013-07-09 | 2022-10-04 | Board Of Trustees Of Michigan State University | Transgenic plants produced with a K-domain, and methods and expression cassettes related thereto |
| WO2015006105A1 (en) | 2013-07-09 | 2015-01-15 | Board Of Trustees Of Michigan State University | Transgenic plants produced with a k-domain, and methods and expression cassettes related thereto |
| US20170166920A1 (en) | 2014-01-30 | 2017-06-15 | Two Blades Foundation | Plants with enhanced resistance to phytophthora |
| US20170081674A1 (en) | 2014-03-14 | 2017-03-23 | Cibus Us Llc | Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair |
| WO2015171603A1 (en) | 2014-05-06 | 2015-11-12 | Two Blades Foundation | Methods for producing plants with enhanced resistance to oomycete pathogens |
| CA2954201A1 (en) | 2014-07-08 | 2016-01-14 | Vib Vzw | Means and methods to increase plant yield |
| US10435700B2 (en) | 2014-10-06 | 2019-10-08 | Altria Client Services Llc | Genetic control of axillary bud growth in tobacco plants |
| WO2016100309A1 (en) | 2014-12-16 | 2016-06-23 | Pioneer Hi-Bred International, Inc. | Restoration of male fertility in wheat |
| WO2016105185A1 (en) | 2014-12-22 | 2016-06-30 | Keygene N.V. | Plant callus populations |
| CN107709564B (zh) | 2015-05-09 | 2021-11-02 | 双刃基金会 | 来自少花龙葵的抗晚疫病基因及使用方法 |
| WO2017062790A1 (en) | 2015-10-09 | 2017-04-13 | Two Blades Foundation | Cold shock protein receptors and methods of use |
| EA201891629A1 (ru) | 2016-02-09 | 2019-03-29 | Сибас Юс Ллс | Способы и композиции для повышения эффективности нацеленной модификации генов с применением опосредуемой олигонуклеотидами репарации генов |
| CN117126815A (zh) | 2016-03-11 | 2023-11-28 | 奥驰亚客户服务有限公司 | 用于生产烟杈减少或消除的烟草植物和制品的组合物和方法 |
| JP7066126B2 (ja) | 2016-08-09 | 2022-05-13 | ブイアイビー ブイゼットダブリュ | セルロースシンターゼ阻害剤および突然変異体植物 |
| EP3523439A1 (en) | 2016-10-07 | 2019-08-14 | Altria Client Services LLC | Composition and methods for producing tobacco plants and products having reduced tobacco-specific nitrosamines (tsnas) |
| CA3047121A1 (en) | 2016-12-16 | 2018-06-21 | Two Blades Foundation | Late blight resistance genes and methods of use |
| US11643432B2 (en) | 2016-12-16 | 2023-05-09 | National University Corporation Tokai National Higher Education And Research System | Nucleoside derivative and use thereof |
| WO2018140214A1 (en) | 2017-01-24 | 2018-08-02 | Pioneer Hi-Bred International, Inc. | Nematicidal protein from pseudomonas |
| WO2019023587A1 (en) | 2017-07-28 | 2019-01-31 | Two Blades Foundation | POTYVIRUS RESISTANCE GENES AND METHODS OF USE |
| EP3682011A1 (en) | 2017-09-11 | 2020-07-22 | Altria Client Services LLC | Compositions and methods for producing tobacco plants and products having reduced or eliminated suckers |
| WO2019088179A1 (ja) | 2017-10-31 | 2019-05-09 | ヤマサ醤油株式会社 | ヌクレオシド誘導体及びその利用 |
| WO2019108619A1 (en) | 2017-11-28 | 2019-06-06 | Two Blades Foundation | Methods and compositions for enhancing the disease resistance of plants |
| US11034969B2 (en) | 2017-12-22 | 2021-06-15 | Altria Client Services Llc | Plant comprising recombinant polynucleotides encoding a pigment regulatory transcription factor with a tissue-preferred promoter |
| CA3087266A1 (en) | 2018-01-09 | 2019-07-18 | Cibus Us Llc | Shatterproof genes and mutations |
| CN111954464A (zh) | 2018-01-12 | 2020-11-17 | 双刃基金会 | 秆锈病抗性基因及使用方法 |
| US11377665B2 (en) | 2018-04-03 | 2022-07-05 | Altria Client Services Llc | Composition and methods for producing tobacco plants and products having increased phenylalanine and reduced tobacco-specific nitrosamines (TSNAs) |
| EP3772905A4 (en) | 2018-04-04 | 2022-01-05 | Cibus US LLC | FAD2 GENES AND MUTATIONS |
| CN113660857A (zh) | 2019-01-24 | 2021-11-16 | 奥驰亚客户服务有限公司 | 包含降低的烟碱和降低的烟草特异性亚硝胺的烟草植物 |
| US20220251595A1 (en) | 2019-06-27 | 2022-08-11 | Two Blades Foundation | Engineered atrlp23 pattern recognition receptors and methods of use |
| US20210071193A1 (en) | 2019-07-12 | 2021-03-11 | The Regents Of The University Of California | Plants with enhanced resistance to bacterial pathogens |
| WO2022240931A1 (en) | 2021-05-11 | 2022-11-17 | Two Blades Foundation | Methods for preparing a library of plant disease resistance genes for functional testing for disease resistance |
| WO2023012342A1 (en) | 2021-08-06 | 2023-02-09 | Kws Vegetables B.V. | Durable downy mildew resistance in spinach |
| WO2023056269A1 (en) | 2021-09-30 | 2023-04-06 | Two Blades Foundation | Plant disease resistance genes against stem rust and methods of use |
| EP4460571A1 (en) | 2022-01-05 | 2024-11-13 | Vib Vzw | Means and methods to increase abiotic stress tolerance in plants |
| WO2023131637A1 (en) | 2022-01-06 | 2023-07-13 | Vib Vzw | Improved silage grasses |
| WO2023144199A1 (en) | 2022-01-26 | 2023-08-03 | Vib Vzw | Plants having reduced levels of bitter taste metabolites |
| WO2025019283A1 (en) | 2023-07-14 | 2025-01-23 | Two Blades Foundation | Methods of improving the thermostability of plant immune receptors |
| WO2025019221A1 (en) | 2023-07-15 | 2025-01-23 | Two Blades Foundation | Broad-spectrum polerovirus resistance gene |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4503151A (en) * | 1980-12-10 | 1985-03-05 | Research Corporation | Recombinant cDNA construction method and hybrid nucleotides useful in cloning |
| US4882279A (en) * | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
| EP0260032B1 (en) * | 1986-09-08 | 1994-01-26 | Ajinomoto Co., Inc. | Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers |
| DK0942000T3 (da) * | 1989-10-24 | 2004-11-01 | Isis Pharmaceuticals Inc | 2'-modificerede oligonukleotider |
| DE69333082T2 (de) * | 1992-02-11 | 2004-05-06 | Cell Genesys, Inc., Foster City | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
| DE733059T1 (de) * | 1993-12-09 | 1997-08-28 | Univ Jefferson | Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen |
| US5760012A (en) * | 1996-05-01 | 1998-06-02 | Thomas Jefferson University | Methods and compounds for curing diseases caused by mutations |
-
1996
- 1996-06-17 US US08/664,487 patent/US5731181A/en not_active Expired - Fee Related
-
1997
- 1997-06-16 CA CA002258090A patent/CA2258090A1/en not_active Abandoned
- 1997-06-16 AU AU34920/97A patent/AU732417B2/en not_active Ceased
- 1997-06-16 JP JP50328298A patent/JP4063326B2/ja not_active Expired - Fee Related
- 1997-06-16 EP EP97931232A patent/EP0968224A4/en not_active Withdrawn
- 1997-06-16 KR KR1019980709232A patent/KR20000011075A/ko not_active Ceased
- 1997-06-16 NZ NZ333201A patent/NZ333201A/en unknown
- 1997-06-16 WO PCT/US1997/010538 patent/WO1997048714A1/en not_active Ceased
- 1997-12-02 US US08/982,867 patent/US5795972A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20000011075A (ko) | 2000-02-25 |
| AU3492097A (en) | 1998-01-07 |
| NZ333201A (en) | 2000-06-23 |
| AU732417B2 (en) | 2001-04-26 |
| EP0968224A4 (en) | 2000-12-06 |
| US5795972A (en) | 1998-08-18 |
| US5731181A (en) | 1998-03-24 |
| JP4063326B2 (ja) | 2008-03-19 |
| JP2000512853A (ja) | 2000-10-03 |
| WO1997048714A1 (en) | 1997-12-24 |
| EP0968224A1 (en) | 2000-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5731181A (en) | Chimeric mutational vectors having non-natural nucleotides | |
| US7053195B1 (en) | Locked nucleic acid containing heteropolymers and related methods | |
| AU708658B2 (en) | Methods and compounds for curing diseases caused by mutations | |
| US5888983A (en) | Method and oligonucleobase compounds for curing diseases caused by mutations | |
| US6211351B1 (en) | Chimeric mutational vectors | |
| JP3585238B2 (ja) | 真核細胞における部位特異的突然変異誘発のための化合物および方法 | |
| US6911575B1 (en) | Targeted manipulation of genes in plants | |
| US6271360B1 (en) | Single-stranded oligodeoxynucleotide mutational vectors | |
| US20030051270A1 (en) | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides | |
| KR20160089530A (ko) | Ｈｂｖ 및 바이러스 질병 및 질환을 위한 ｃｒｉｓｐｒｃａｓ 시스템 및 조성물의 전달，용도 및 치료적 적용 | |
| JP2003528607A (ja) | 修飾一本鎖オリゴヌクレオチドを使用した標的染色体ゲノム変換 | |
| EP1078097A1 (en) | Cell-free chimeraplasty and eukaryotic use of heteroduplex mutational vectors | |
| KR20210134000A (ko) | Rna-가이드된 엔도뉴클레아제를 사용한 dna 통합을 위한 개선된 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20090616 |